Cargando…
SARS-CoV-2 and Epstein–Barr Virus-like Particles Associate and Fuse with Extracellular Vesicles in Virus Neutralization Tests
The successful development of effective viral vaccines depends on well-known correlates of protection, high immunogenicity, acceptable safety criteria, low reactogenicity, and well-designed immune monitoring and serology. Virus-neutralizing antibodies are often a good correlate of protective immunit...
Autores principales: | Roessler, Johannes, Pich, Dagmar, Krähling, Verena, Becker, Stephan, Keppler, Oliver T., Zeidler, Reinhard, Hammerschmidt, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669694/ https://www.ncbi.nlm.nih.gov/pubmed/38001893 http://dx.doi.org/10.3390/biomedicines11112892 |
Ejemplares similares
-
Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test
por: Roessler, Johannes, et al.
Publicado: (2022) -
Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection
por: Akidil, Ezgi, et al.
Publicado: (2021) -
First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus
por: Pich, Dagmar, et al.
Publicado: (2019) -
Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection
por: Mrozek-Gorska, Paulina, et al.
Publicado: (2019) -
Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model
por: Reguraman, Narendran, et al.
Publicado: (2023)